Chris Phelps
About Chris Phelps
Chris Phelps serves as the Area Director of Surgical Glaucoma at Sight Sciences, Inc. since 2021, bringing extensive experience from previous roles in sales and strategic account management within the ophthalmic industry.
Work at Sight Sciences
Chris Phelps has been serving as the Area Director Surgical Glaucoma at Sight Sciences, Inc. since 2021. In this role, he focuses on the surgical glaucoma segment, contributing to the company's growth and development in this specialized area. Prior to his current position, he worked as the Director of Sales Surgical Glauco at the same company from 2018 to 2021. His experience at Sight Sciences spans a total of three years.
Previous Experience at Alcon
Before joining Sight Sciences, Chris Phelps held several positions at Alcon. He served as the Global Head of Strategic Account Management from 2013 to 2015, where he managed key accounts on a global scale. Following this role, he was the Director of Academic Development for US Professional Affairs from 2015 to 2017. He also worked as the Senior Manager of HCP Education and Training for US Surgical Sales from 2017 to 2018. His tenure at Alcon provided him with extensive experience in the ophthalmic industry.
Education and Expertise
Chris Phelps earned a Bachelor of Arts (B.A.) in Psychology from the University of Iowa, where he studied from 1990 to 1995. His educational background in psychology complements his professional experience in the medical field, particularly in surgical glaucoma and ophthalmic sales. This foundation has likely contributed to his understanding of client needs and strategic account management.
Career Timeline
Chris Phelps has a diverse career spanning multiple roles in the ophthalmic industry. He began his professional journey at Alcon in 2013 and transitioned to Sight Sciences in 2018. His career includes significant positions that highlight his expertise in sales, account management, and education within the surgical glaucoma sector. His current role as Area Director Surgical Glaucoma marks a continuation of his commitment to advancing the field.